Equillium, INC Form 4 insider transactions

Equillium, Inc. Senior Vice President and COO Christine Zedelmayer exercised options and sold 14,584 shares of common stock.

Equillium, Inc. President and CSO Stephen Connelly reported the sale of 230,975 shares of common stock across two days in June 2026.

Principal Accounting Officer Tom Penny exercised options and sold 65,000 shares of Equillium, Inc. common stock.

Director Martha J. Demski was granted 70,000 stock options in Equillium, Inc. as part of a standard equity compensation package.

Equillium, Inc. director Mark Pruzanski was granted 70,000 stock options as part of his compensation package.

Equillium, Inc. Chairman Daniel Bradbury was granted 70,000 stock options as part of his director compensation package.

Equillium, Inc. Senior Vice President and COO Christine Zedelmayer exercised stock options and sold shares under a Rule 10b5-1 trading plan.

Director Charles Douglas McDermott was granted 70,000 stock options in Equillium, Inc. as part of a standard equity incentive.

Director Barbara Troupin was granted 70,000 stock options in Equillium, Inc. as part of a standard equity compensation arrangement.

Equillium's Senior Vice President and COO, Christine Zedelmayer, exercised stock options and subsequently sold 120,312 shares of common stock as part of a pre-arranged 10b5-1 trading plan.

Equillium's Sr. Vice President and COO, Christine Zedelmayer, exercised stock options and subsequently sold a portion of the acquired common stock under a pre-arranged 10b5-1 trading plan.

Equillium, Inc. granted 1,150,000 employee stock options to Stephen Connelly, President and CSO, with an exercise price of $1.31.

Equillium, Inc.'s Senior Vice President and Chief Operating Officer, Christine Zedelmayer, was granted 500,000 employee stock options with an exercise price of $1.31.

Equillium, Inc. CEO Bruce D. Steel was granted 1.75 million employee stock options with an exercise price of $1.31, vesting over four years.

Equillium's Principal Accounting Officer, Tom Penny, reported the sale of common stock and the acquisition of new employee stock options.

Equillium's Senior Vice President and COO, Christine Zedelmayer, exercised stock options and subsequently sold 100,000 shares of common stock.

Equillium's Senior Vice President and COO, Christine Zedelmayer, sold a total of 35,704 shares of common stock in December 2025 through a pre-arranged 10b5-1 trading plan.

Equillium's Senior Vice President and COO, Christine Zedelmayer, sold 8,098 shares of common stock through a pre-arranged Rule 10b5-1 trading plan.

Equillium's Chief Scientific Officer and Director, Stephen Connelly, was granted 1,025,000 employee stock options with an exercise price of $1.74.

Equillium, Inc. granted its Principal Accounting Officer, Tom Penny, 525,000 employee stock options with an exercise price of $1.74.

Equillium, Inc.'s Senior Vice President and Chief Operating Officer, Christine Zedelmayer, was granted 725,000 employee stock options with an exercise price of $1.74.

Equillium, Inc. President and CEO, Bruce D. Steel, was granted 1,695,000 employee stock options with an exercise price of $1.74.

Equillium, Inc. Director Peter Colabuono was granted 20,000 stock options with an exercise price of $0.39, vesting over twelve months or until the next annual stockholder meeting.

Equillium, Inc. director Martha J. Demski was granted 20,000 stock options with an exercise price of $0.39, vesting over twelve months or until the next annual stockholders' meeting.

Equillium, Inc. Director Mark Pruzanski was granted 20,000 stock options with an exercise price of $0.39, aligning his interests with shareholder value.

Equillium, Inc. Director Charles Douglas McDermott was granted 20,000 stock options with an exercise price of $0.39, aligning his interests with shareholders.

Equillium, Inc. Director Barbara Troupin was granted 20,000 stock options with an exercise price of $0.39, aligning her interests with shareholders.

Equillium, Inc. Director Bala S Manian has acquired 20,000 stock options with an exercise price of $0.39, granted on May 21, 2025, as part of a compensation package.

Christine Zedelmayer, Sr. Vice President and COO of Equillium, Inc., reports the repricing of employee stock options and related transactions following the lapse of a holding period.

Stephen Connelly, Chief Scientific Officer of Equillium, Inc., reports the repricing of employee stock options and related transactions following the lapse of a holding period.